




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Immunity

## Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections

### Graphical abstract



### Authors

Hani Harb, Mehdi Benamar, Peggy S. Lai, ..., Gunnur Deniz, Raffaele De Palma, Talal A. Chatila

### Correspondence

talal.chatila@childrens.harvard.edu

### In brief

Harb, Benamar, et al. find that interleukin-6 increases Notch4 expression on lung regulatory T cells, which, in turn, restrains production of the tissue repair cytokine amphiregulin and promotes severe lung inflammation. Their findings have implications for treatment of COVID-19 and other respiratory viral infections.

### Highlights

- Notch4 expression on Treg cells is associated with COVID-19 disease severity
- Notch4 inhibition suppresses lung inflammation in proxy viral mouse models
- Notch4 limits amphiregulin-dependent lung Treg cell tissue repair functions



## Article

# Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections

Hani Harb,<sup>1,2,17</sup> Mehdi Benamar,<sup>1,2,17</sup> Peggy S. Lai,<sup>3,4,17</sup> Paola Contini,<sup>5,6</sup> Jason W. Griffith,<sup>3,4</sup> Elena Crestani,<sup>1,2</sup> Klaus Schmitz-Abe,<sup>1,2</sup> Qian Chen,<sup>1,2</sup> Jason Fong,<sup>1,2</sup> Luca Marri,<sup>6</sup> Gilberto Filaci,<sup>7</sup> Genny Del Zotto,<sup>8</sup> Novalia Pishesha,<sup>2,9</sup> Stephen Kolifrath,<sup>2,9</sup> Achille Broggi,<sup>1,2</sup> Sreya Ghosh,<sup>1,2</sup> Metin Yusuf Gelmez,<sup>10</sup> Fatma Betul Oktelik,<sup>10</sup> Esin Aktas Cetin,<sup>10</sup> Ayca Kiykim,<sup>11</sup> Murat Kose,<sup>12</sup> Ziwei Wang,<sup>1,2</sup> Ye Cui,<sup>1,2</sup> Xu G. Yu,<sup>13</sup> Jonathan Z. Li,<sup>14</sup> Lorenzo Berra,<sup>15</sup> Emmanuel Stephen-Victor,<sup>1,2</sup> Louis-Marie Charbonnier,<sup>1,2</sup> Ivan Zanoni,<sup>1,2</sup> Hidde Ploegh,<sup>2,9</sup> Gunnur Deniz,<sup>10</sup> Raffaele De Palma,<sup>5,6,16,18</sup> and Talal A. Chatila<sup>1,2,18,19,\*</sup>

<sup>1</sup>Division of Immunology, Boston Children's Hospital, Boston, MA, USA

<sup>2</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, USA

<sup>3</sup>Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA

<sup>4</sup>Department of Medicine, Harvard Medical School, Boston, MA, USA

<sup>5</sup>Department of Internal Medicine, University of Genoa, Genoa, Italy

<sup>6</sup>Unit of Clinical Immunology and Translational Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

<sup>7</sup>Biotherapy Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

<sup>8</sup>Department of Research and Diagnostics, IRCCS Istituto Giannina Gaslini, Genoa, Italy

<sup>9</sup>Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, USA

<sup>10</sup>Department of Immunology, Aziz Sancar Institute of Experimental Medicine (Aziz Sancar DETAE), Istanbul University, Istanbul, Turkey

<sup>11</sup>Division of Pediatric Allergy and Immunology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

<sup>12</sup>Department of Internal Medicine, Faculty of Medicine, Istanbul University, Istanbul, Turkey

<sup>13</sup>Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard Medical School, Boston, MA, USA

<sup>14</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>15</sup>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

<sup>16</sup>CNR-Institute of Biomolecular Chemistry (IBC), Via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy

<sup>17</sup>These authors contributed equally

<sup>18</sup>These authors contributed equally

<sup>19</sup>Lead contact

\*Correspondence: [talal.chatila@childrens.harvard.edu](mailto:talal.chatila@childrens.harvard.edu)

<https://doi.org/10.1016/j.immuni.2021.04.002>

## SUMMARY

A cardinal feature of COVID-19 is lung inflammation and respiratory failure. In a prospective multi-country cohort of COVID-19 patients, we found that increased Notch4 expression on circulating regulatory T (Treg) cells was associated with disease severity, predicted mortality, and declined upon recovery. Deletion of *Notch4* in Treg cells or therapy with anti-Notch4 antibodies in conventional and humanized mice normalized the dysregulated innate immunity and rescued disease morbidity and mortality induced by a synthetic analog of viral RNA or by influenza H1N1 virus. Mechanistically, Notch4 suppressed the induction by interleukin-18 of amphiregulin, a cytokine necessary for tissue repair. Protection by Notch4 inhibition was recapitulated by therapy with Amphiregulin and, reciprocally, abrogated by its antagonism. Amphiregulin declined in COVID-19 subjects as a function of disease severity and Notch4 expression. Thus, Notch4 expression on Treg cells dynamically restrains amphiregulin-dependent tissue repair to promote severe lung inflammation, with therapeutic implications for COVID-19 and related infections.

## INTRODUCTION

The current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has resulted in massive morbidity and mortality in the United States and globally (Cucinotta and Vanelli, 2020). Although many infected subjects are asymptomatic or have a mild form of the disease, a subset suffers from more severe disease with pneumonia and marked

hypoxia, leading to acute respiratory distress syndrome (Berlin et al., 2020; Richardson et al., 2020; Zhou et al., 2020a). In many of those individuals, the disease proves fatal despite intensive respiratory support. Uncontrolled activation of the immune response, leading to a cytokine storm, is a key risk factor for mortality (Henderson et al., 2020; Lucas et al., 2020; Vabret et al., 2020). The molecular mechanisms governing lung disease severity are not yet well understood. Notably, innate immune



cell hyperactivation plays a critical role in the pathogenesis of severe coronavirus disease 2019 (COVID-19) (Del Valle et al., 2020; Vabret et al., 2020; Zhou et al., 2020b), a finding also recapitulated in emerging mouse models (Winkler et al., 2020). Among the innate immune cytokines, interleukin-6 (IL-6) has been proposed to play a pathogenic role because of its increased serum concentrations in subjects with severe COVID-19 and reports of favorable clinical responses to anti-IL-6 receptor (IL-6R) monoclonal antibody (mAb) therapy (Copaescu et al., 2020; The REMAP-CAP Investigators, 2021; Salama et al., 2021; Toniati et al., 2020; Xu et al., 2020). Other studies, however, have failed to confirm such a benefit (Hermine et al., 2021; Rosas et al., 2021; Salvarani et al., 2021; Veiga et al., 2021).

An IL-6-dependent pathway subverts lung regulatory T (Treg) cells to promote tissue inflammation in severe asthma by increasing Treg cell expression of the receptor Notch4 (Harb et al., 2020; Xia et al., 2015, 2018). In this setting, Notch4 acts via downstream pathways, including Hippo and Wnt, to disrupt Treg cell regulation of the T helper type 2 (Th2) and Th17 adaptive immune responses. In case studies, treatment of individuals with severe asthma with the anti-IL-6R mAb tocilizumab decreased Notch4 expression on circulating Treg cells and improved disease outcomes (Esty et al., 2019).

The *NOTCH4* locus is associated with critical illness in COVID-19 (Pairo-Castineira et al., 2021). Given this and the evidence supporting a pathogenic role for high levels of IL-6 in COVID-19, we examined the effect of inducible Notch4 expression on Treg cells in lung viral infection, including COVID-19. We found increased Notch4 expression in subjects with COVID-19 as a function of disease severity. In mouse models of respiratory viral infections, Notch4 enabled virus-induced tissue inflammation by mechanisms distinct from those involved in its regulation of adaptive immunity in allergic airway inflammation. Rather, Notch4 expression inhibited Treg-cell-mediated regulation of innate immune responses and promotion of tissue repair. The protective function of Notch4 inhibition involved increased production by Treg cells of the epidermal growth factor-like cytokine amphiregulin, which plays a critical role in mediating tissue repair by Treg cells in lung viral infections (Arpaia et al., 2015). These findings identify Notch4 as an effector of COVID-19 disease severity and point to interventions along the Notch4-amphiregulin axis as a viable therapeutic strategy to restore immune regulation in severe viral respiratory infections, including COVID-19.

## RESULTS


### Treg cell Notch4 expression is independently predictive of mortality from COVID-19

To determine the association between Notch4 and disease severity in individuals with COVID-19, we recruited three cohorts of people with COVID-19 as well as healthy control individuals from Boston, Massachusetts ( $n = 38$  and  $n = 10$ , respectively); Genoa, Italy ( $n = 44$  and  $n = 10$ ); and Istanbul, Turkey ( $n = 36$  and  $n = 20$ ) (Table S1). The subjects were segregated into three disease severity groups (mild, moderate, and severe) based on the need for hospitalization and advanced respiratory support as well as a convalescent group, following criteria detailed in the STAR Methods. Older male individuals with a history of malignancy, cardiac disease, or endocrine disease had more severe

disease (Table S1). Frequencies, absolute numbers, and mean fluorescence intensity (MFI) of Notch4 expression on peripheral blood CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Treg cells of COVID-19 subjects in the different cohorts increased progressively as a function of disease severity and declined precipitously in the convalescent subjects (Figures 1A and 1B; Table S1). In contrast, there was a modest increase in Notch4 expression on CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>-</sup> T effector (Teff) cells of subjects with moderate and severe disease and otherwise minimal expression in the other subject groups (Figures 1C and 1D). Also, there was no difference in expression of the other Notch receptors, including Notch1, Notch2, and Notch3, on circulating Treg cells among subjects in the different study groups (Figure S1). In multivariate logistic regression adjusting for age, gender, comorbidities, glucocorticoid treatment, and serum IL-6 levels, each 1% increase in Notch4 expression in Treg cells was independently associated with 1.046 higher odds of mortality (univariate odds ratio 1.052 [95% confidence interval (CI) 1.020–1.088],  $p = 0.002$ ; multivariate odds ratio 1.046 [95% CI 1.008–1.090],  $p = 0.023$ ) (Table S1). For example, an increase in Treg cells expressing Notch4 by 10% in a 65-year-old male individual with a history of malignancy treated with steroids would lead to a rise in predicted mortality from 28.4% to 38.3%. Overall, serum IL-6 concentrations were correlated positively with Treg cell Notch4 expression (Figure 1E). Moreover, the serum concentrations of interferon alpha (IFN $\alpha$ ), IFN $\beta$ , and IFN $\gamma$  were decreased in individuals with moderate and severe disease compared with those with mild disease (Figure 1F; Blanco-Melo et al., 2020; Hadjadj et al., 2020). In contrast, the serum concentrations of other cytokines, including IL-1 $\beta$ , tumor necrosis factor (TNF), IL-8, IL-10, and IL-12p70, were unchanged, whereas those of CXCL10 were slightly increased in subjects with severe disease (Figure 1G).

### Treg cell Notch4 promotes lung tissue inflammation induced by polyinosinic:polycytidylic acid (poly(I:C))

To investigate the mechanism by which Notch4 licenses lung tissue inflammation in viral respiratory infections, we first examined its role in poly(I:C)-induced airway inflammation. Poly(I:C) stimulates Toll-like receptor 3 and the downstream viral RNA sensors cytoplasmic retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), providing a proxy model of RNA viral infection (Broggi et al., 2020; Iwasaki and Pillai, 2014; Kato et al., 2006). Daily intratracheal instillation of poly(I:C) in mice for 6 consecutive days resulted in sharp progressive increases in the frequencies and absolute numbers of Notch4-expressing lung tissue Treg cells as well as in the MFI of Notch4 on those cells (Figures 2A–2C). In contrast, minimal expression of Notch4 was noted on CD4<sup>+</sup> Teff cells. Treg cell-specific deletion of *Notch4* using a *Foxp3*-driven Cre recombinase (*Foxp3*<sup>YFPCre</sup>) and floxed *Notch4* allele (*Foxp3*<sup>YFPCre</sup>*Notch4* <sup>$\Delta/\Delta$</sup> ) or treatment with an anti-Notch4 neutralizing mAb, but not an isotype control mAb, protected mice from weight loss induced by poly(I:C) treatment (Figures 2D and 2E). Histopathological analysis revealed intense inflammation in the lungs of poly(I:C)-treated mice that was suppressed by Notch4 antagonism (Figures 2F and 2G). Similarly, airway hyperresponsiveness (AHR), which was increased in poly(I:C)-treated mice, was also normalized (Figure 2H). Analysis of bronchoalveolar lavage (BAL) fluid revealed increased IL-6 concentrations in poly(I:C)-treated mice that



**Figure 1. Increased expression of Notch4 on circulating Treg cells of subjects with COVID-19**

(A–D) Flow cytometry analysis, cell frequencies, absolute numbers, and MFI of Notch4 expression in Treg cells (A and B) and Teff cells (C and D) of control subjects and subjects with mild, moderate, severe, or resolved COVID-19 (healthy control subjects, n = 37; mild disease, n = 20; moderate disease, n = 54; severe disease, n = 36; convalescent subjects, n = 6).

(E) Serum concentrations of IL-6 in the different subject groups (healthy control subjects, n = 37; mild disease, n = 18; moderate disease, n = 45; severe disease, n = 21).

(F) Correlation analysis of Notch4 expression on Treg cells of affected and control subjects as a function of serum IL-6 concentrations (n = 121).


(G) Serum concentrations of IFN $\alpha$ , IFN $\beta$ , IFN $\gamma$ , IFN $\lambda$ , CXCL10, IL-1 $\beta$ , IL-8, IL-10, IL-12, and TNF in control and affected subjects (healthy control subjects, n = 37; mild disease, n = 18; moderate disease, n = 45; severe disease, n = 21).

Each symbol represents one subject. Numbers in flow plots indicate percentages. Error bars indicate SEM. Statistical tests: \*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.0001 by one-way ANOVA with Dunnett’s post hoc analysis (A–E and G) and Pearson correlation analysis (D). Data represent a pool of two or three independent experiments.

were suppressed upon Notch4 inhibition, consistent with decreased inflammation (Figure 2I). A similar increase was also noted for a number of other cytokines, including IFN $\gamma$ , IL-1 $\alpha$ , IL-1 $\beta$ , TNF- $\alpha$ , IFN $\beta$ , MCP1, GM-CSF, IL-17, oncostatin M, leukemia inhibitory factor, and CXCL5, most of which were also suppressed by Notch4 antagonism (Figure S3A). Further analysis revealed that Notch4 inhibition suppressed lung tissue neutrophil infiltration induced by poly(I:C) treatment and reversed the increase in lung M1 macrophages while increasing M2 macro-

phages (Figure 2J). *In vitro* co-cultures of poly(I:C)-treated macrophages with lung Treg cells derived from poly(I:C)-treated mice revealed that *Foxp3*<sup>YFP-Cre</sup> *Notch4* <sup>$\Delta/\Delta$</sup>  but not *Foxp3*<sup>YFP-Cre</sup> Treg cells reversed the M1 skewing and promoted M2 macrophage differentiation (Figure 2K). These results confirmed a critical role of Treg cell Notch4 expression in the evolution of lung inflammation induced by poly(I:C).

Different Notch receptors control Treg cell function (Charbonnier et al., 2015; Ostroukhova et al., 2006; Perumalsamy et al.,



**Figure 2. Protective effect of Notch4 inhibition in poly(I:C)-induced lung injury**

(A and B) Flow cytometry analysis (A) and cell frequencies, absolute numbers, and MFI (B) of Notch4 expression in lung, mediastinal lymph node (medLN), and spleen Treg and Teff cells of *Foxp3<sup>YFP/Cre</sup>* mice treated with PBS or poly(I:C) once daily for 6 days.

(C) Notch4 expression on lung, medLN, and spleen Treg cells of *Foxp3<sup>YFP/Cre</sup>* mice.

(D and E) Weight index (D) and peak weight loss (E) of *Foxp3<sup>YFP/Cre</sup>* and *Foxp3<sup>YFP/Cre</sup>Notch4<sup>Δ/Δ</sup>* mice treated with PBS or poly(I:C) together with an isotype control or anti-Notch4 mAb.

(F) Hematoxylin and eosin-stained sections of lung tissues (200× magnification).

(G) Inflammation scores.

(H) AHR in response to methacholine. RI, responsiveness index (a measure of airway resistance).

(I and J) BAL fluid IL-6 concentrations (I) and graphical representation of lung tissue neutrophils and M1 and M2 macrophages.

(K) M1 and M2 macrophage frequencies in cultures of poly(I:C)-treated lung macrophages incubated with Treg cells from the indicated poly(I:C)-treated mice.

(L) Flow cytometry analysis of IL-6Rα expression in lung Notch4<sup>+</sup> or Notch4<sup>-</sup> Treg cells of *Foxp3<sup>YFP/Cre</sup>* mice treated with poly(I:C).

(M) *In vitro* induction of Notch4 expression in Treg cells from the lungs or spleens of poly(I:C) or PBS-treated *Foxp3<sup>YFP/Cre</sup>* mice. Each symbol represents one mouse (n = 5–15 per group).

Numbers in flow plots indicate percentages. Error bars indicate SEM. Statistical tests: Student's t test (B), one-way ANOVA with Dunnett's post hoc analysis (E, G, and I–K), and two-way ANOVA with Sidak's post hoc analysis (C, D, H, and L). \*\*\*p < 0.001, \*\*\*\*p < 0.0001. Data were pooled from two or three independent experiments.

2012). However, the role of Notch4 in licensing lung tissue inflammation by poly(I:C) was highly specific in that Treg cell-specific deletion of the other Notch genes, including *Notch1*, *Notch2*, and *Notch3*, failed to protect against tissue inflammation. In contrast, Treg cell-specific deletion of *Rbpj*, encoding the Notch canonical pathway transcription factor RBPJ, largely reproduced the protective effect of *Notch4* deletion (Figures S2A–S2F). Downstream of Notch4, our previous studies have implicated the Hippo and Wnt pathways in Treg cell regulation of Th17 and Th2 responses in allergic airway inflammation, respectively (Harb et al., 2020). Poly(I:C) treatment potently induced expression of the Hippo pathway effector Yap in lung tissue Treg cells, whereas expression of the Wnt pathway effector  $\beta$ -catenin was unchanged (Figures S2G and S2H). Treg cell-specific deletion of *Yap1* and *Wwtr1*, encoding the Hippo pathway effectors Yap and Taz; *Cttnb1*, encoding the Wnt pathway effector  $\beta$ -catenin; or all three genes failed to protect against poly(I:C)-induced inflammation. These findings indicate that Notch4 regulation of the acute inflammatory responses to viral infection proceeds by distinct mechanisms (Figures S2I–S2N).

We have previously identified a key role of IL-6 in upregulating Notch4 expression on Treg cells in asthmatic inflammation (Harb et al., 2020). Consistent with these results, Notch4<sup>+</sup> lung Treg cells from poly(I:C)-treated mice expressed higher levels of IL-6 receptor alpha chain (IL-6R $\alpha$ ) compared with their Notch4<sup>-</sup> counterparts (Figure 2L). To further elucidate the mechanisms of Notch4 induction in Treg cells, we conducted *in vitro* studies to examine the capacity of poly(I:C) and cytokine treatment to upregulate Notch4 expression in Treg cells isolated from PBS or poly(I:C)-treated mice. The results showed that poly(I:C) treatment of lung but not splenic Treg cells increased Notch4 expression in synergy with IL-6 but not IL-33 (Figure 2M). *In vivo*, Treg cell-specific deletion of *Il6ra* attenuated poly(I:C)-induced Notch4 expression on lung Treg cells and the attendant tissue inflammatory response, including the decline in body weight, increase in AHR, influx of neutrophils, and alteration in macrophage populations (Figures S3B–S3G). These results indicate that IL-6 and additional signals contribute to Notch4 upregulation on lung Treg cells in poly(I:C)-treated mice.


### Notch4 promotes lung inflammation induced by H1N1 influenza A virus

To extend these findings to an RNA virus model, we analyzed the role of Notch4 expression on Treg cells in licensing lung tissue inflammation in a mouse model of H1N1 influenza A virus infection (Woodham et al., 2020). In studies where mice were infected with H1N1 virus at  $4 \times 10^4$  plaque-forming units (PFUs)/mouse, the weight loss induced by the infection was abrogated by prior treatment with a neutralizing anti-Notch4 mAb or upon Treg cell-specific deletion of *Notch4* (Figures 3A and 3B). Notch4 antagonism suppressed the virus-induced increase in BAL fluid IL-6 concentration (Figure 3C). It also suppressed induction by viral infection of a number of other inflammatory cytokines, similar to what was noted for with poly(I:C) treatment (Figure S4A). It also reversed the lung tissue inflammatory response in infected mice (Figure 3D). Antagonism of Notch4 expression did not result in increased viral loads, as measured on days 7 and 12 af-

ter infection (Figure 3E). Analysis of Notch4 expression on lung Treg cells in the respective mouse groups revealed that H1N1 infection increased Notch4 expression, an effect abrogated by treatment with an anti-Notch4 mAb or by Treg cell-specific *Notch4* deletion (Figure 3F). Both interventions greatly attenuated lung tissue neutrophil influx, restored the alveolar macrophage population, and reversed skewing of tissue macrophages away from the pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype (Figures S4B–S4D). Notch4 inhibition did not affect the frequencies of IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> or IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells or IFN $\gamma$ <sup>+</sup> macrophages infiltrating the lungs of infected mice, whereas those of IFN $\gamma$ <sup>+</sup> innate lymphoid cells 1 (ILC1s) were decreased. Nevertheless, the absolute numbers of all four populations were decreased sharply, consistent with the markedly attenuated inflammatory response (Figures S5A–S5F). Notch4 inhibition also decreased the frequencies and absolute numbers of lung tissue IL-17<sup>+</sup> CD4 and CD8 T cells (Figures S5G and S5H).

To determine the capacity of Notch4 antagonism to rescue active disease, mice were infected with the same dose of H1N1 virus and were treated with an isotype control mAb or with an anti-Notch4 mAb following onset of infection. The results revealed that treatment of mice with the anti-Notch4 mAb on day 4 or on days 4 and 7 after infection rescued mice from death, whereas only day 4 and 7 treatment suppressed the weight loss and innate immune activation associated with infection (Figures 3G and 3H). Both anti-Notch4 mAb treatment regimens suppressed the increase in BAL fluid IL-6 and IFN $\gamma$  concentrations induced by the viral infection (Figure 3I). We further compared different anti-Notch4 mAb treatment regimens for their capacity to rescue mice from a lethal dose 75% (LD75) of H1N1 virus (at  $7 \times 10^4$  PFU/mouse). Treatment with the anti-Notch4 mAb on days 2, 6, and 10 was associated with decreased mortality (22%). In contrast, treatment with an isotype control mAb or with an anti-IL-6R $\alpha$  mAb failed to protect the mice from exacerbated mortality (62% and 72% mortality, respectively) (Figure 3J). These results indicate that therapy with an anti-Notch4 mAb protects mice from active influenza virus infection.

To extend the above results to the setting of a humanized immune system mouse model, we analyzed the capacity of neutralizing anti-human Notch4 mAbs to rescue disease in non-obese diabetic (NOD)-*Prkdc*<sup>scid</sup>*Il2rg*<sup>tm1wjl</sup>/Sz (NSG) mice reconstituted with human peripheral blood mononuclear cells (PBMCs) and infected with the H1N1 virus (Verma et al., 2017). Neutralizing mAbs specific for Notch4, but not other Notch proteins, were derived by immunizing mice with a recombinant N-terminal human Notch4 protein fragment (amino acids 1–637) (Figures S6A and S6B). Treatment of mice with one neutralizing anti-human Notch4 mAb (clone 4H1), but not an isotype control mAb, protected against H1N1 virus infection-induced weight loss and tissue inflammation (Figures 4A–4D). Another neutralizing antibody (clone 3B11) was partially protective. Both antibodies inhibited Notch4 expression on lung Treg cells (Figure 4E) and inhibited macrophage skewing, neutrophil infiltration, and production of the cytokines IL-6 and IFN $\gamma$  (Figures 4F–4I). The antibody treatment did not affect virus clearance, as measured by virus copy numbers in lung tissue (Figure 4J). These results confirm that Notch4 regulates the magnitude of the human inflammatory



**Figure 3. Protective effect of Notch4 inhibition in influenza A H1N1 virus infection**

(A and B) Weight index (A) and peak weight loss (B) of *Foxp3*<sup>YFP<sup>Cre</sup> and *Foxp3*<sup>YFP<sup>Cre</sup>*Notch4*<sup>Δ/Δ</sup> mice that were sham treated or infected with a 40,000-PFU dose of H1N1 virus alone or together with an anti-Notch4 mAb, as indicated. Arrows indicate the time of antibody treatment. (C) BAL fluid IL-6 concentrations in the indicated groups. (D) Hematoxylin and eosin-stained sections and inflammation score of lung tissue isolated from the indicated mouse groups (200× magnification). (E) Viral load (viral copies per gram of tissue) in the respective mouse groups (n = 5 per group). (F) Flow cytometry analysis and graphical representation of Notch4 expression in lung tissue Treg cells of the respective *Foxp3*<sup>YFP<sup>Cre</sup> and *Foxp3*<sup>YFP<sup>Cre</sup>*Notch4*<sup>Δ/Δ</sup> mouse groups. (G and H) Weight index and peak weight loss (G) and survival (H) of *Foxp3*<sup>YFP<sup>Cre</sup> mice that were sham treated or infected with a 40,000-PFU dose of H1N1 virus alone or together with an anti-Notch4 mAb, as indicated. Arrows indicate the time of antibody treatment. (I) BAL fluid IL-6 and IFN $\gamma$  concentrations. (J) Survival curve of *Foxp3*<sup>YFP<sup>Cre</sup> mice that were sham treated or infected with a lethal dose of H1N1 virus alone or together with an anti-Notch4 or anti-IL-6R $\alpha$  mAb, as indicated.</sup></sup></sup></sup></sup></sup>

Each symbol represents one mouse (n = 5–23). Numbers in flow plots indicate percentages. Error bars indicate SEM. Statistical tests: one-way ANOVA with Dunnett’s post hoc analysis (B, C, F, I, and J) and two-way ANOVA with Sidak’s post hoc analysis (A, D, E, G, and K). \*p < 0.05, \*\*\*p < 0.001, \*\*\*\*p < 0.0001. Data were pooled from two or three independent experiments.

response to H1N1 infection and that it can be targeted successfully for therapeutic intervention.


### Protection by Notch4 antagonism is amphiregulin dependent

To better understand the mechanisms by which Notch4 deficiency protected against lung inflammation, we analyzed the transcriptomes of lung Treg cells of *Foxp3*<sup>YFP<sup>Cre</sup> and *Foxp3*<sup>YFP<sup>Cre</sup>*Notch4*<sup>Δ/Δ</sup> mice treated with poly(I:C) for 6 days. The results revealed that lung Treg cells of poly(I:C)-treated *Foxp3*<sup>YFP<sup>Cre</sup> mice exhibited an activated effector Treg cell signature, with upregulation of many canonical Treg cell transcripts, including *Ctla4*, *Ikzf2*, *Il10*, and *Tigit* and the TNF receptor superfamily members *Tnfrsf4*, *Tnfrsf9*, and *Tnfrsf18* (Arpaia et al., 2015; Figures 5A and 5B). Poly(I:C) treatment also imparted an exhausted T cell-like signature with increased *Pdcd1*, *Icos*, *Lag3*, and other related transcripts that may impair their suppressive function (Lowther et al., 2016). In contrast, Treg cells of poly(I:C)-treated *Foxp3*<sup>YFP<sup>Cre</sup>*Notch4*<sup>Δ/Δ</sup> mice increased several type I IFN genes. More broadly, key pathways enriched</sup></sup></sup></sup>

in *Foxp3*<sup>YFP<sup>Cre</sup> versus *Foxp3*<sup>YFP<sup>Cre</sup>*Notch4*<sup>Δ/Δ</sup> lung Treg cells included those involved in innate virus sensing and response, type I IFN signaling, T<sub>H</sub> cell differentiation, and ubiquitin-mediated proteolysis (Figure 5C). Although the RNA and protein expression of several key canonical markers was increased concordantly in *Foxp3*<sup>YFP<sup>Cre</sup> lung Treg cells, exceptions included the transcription factor Helios, encoded by *Ikzf2*, whose expression was decreased despite increased transcript levels (Figure 5D). Further analysis localized the loss of Helios expression to the Notch4<sup>+</sup> fraction of *Foxp3*<sup>YFP<sup>Cre</sup> lung Treg cells, suggesting an expansion of Helios<sup>low</sup> Notch4<sup>+</sup>-induced Treg cells, similar to our observation in the asthma model (Harb et al., 2020), or loss of Helios expression leading to an increased potential for destabilization (Thornton et al., 2019; Figure 5E). The latter results suggest that Notch4 initiated a program of post-translational regulation by pathways such as ubiquitination and proteolysis, both of which were increased in Treg cells of poly(I:C)-treated *Foxp3*<sup>YFP<sup>Cre</sup> mice.</sup></sup></sup></sup></sup>

The function of Treg cells in lung tissue repair in H1N1 virus infection involves production of the epidermal growth





**Figure 4. Notch4 licenses viral lung inflammation in humanized mice**

(A) Schematic of humanized mouse infection with H1N1 influenza virus and treatment with neutralizing anti-human Notch4 mAbs.

(B) Weight index of mice that were infected with a sublethal dose of H1N1 virus and treated with an isotype control mAb or anti-Notch4 mAb 3B11 or 4H1, as indicated.

(C and D) Hematoxylin and eosin-stained sections and inflammation score of lung tissue isolated from the indicated mouse groups (200× magnification).

(E) Flow cytometry analysis and frequencies of Notch4 expression in lung Treg cells of the respective groups.

(F and G) Flow cytometry analysis and graphical representation of lung tissue M1 (F) and M2 macrophages (G).

(H) Neutrophil infiltration in the lungs of the respective mouse groups.

(I) BAL fluid IL-6 and IFN $\gamma$  concentrations.

(J) Viral load in the respective mouse groups, measured as viral copies per 100 ng lung tissue RNA.


Each symbol represents one mouse (n = 4–5 per group). Numbers in flow plots indicate percentages. Error bars indicate SEM. Statistical tests: two-way ANOVA with Sidak's post hoc analysis (B) and one-way ANOVA with Dunnett's post hoc analysis (D–J). \*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.0001.

factor-like cytokine amphiregulin (Arpaia et al., 2015). Treg cells are the main source of amphiregulin in the lungs, whereas Treg cell-specific deletion of *Areg*, the gene encoding amphiregulin, worsens disease outcome (Arpaia et al., 2015). Analysis of lung Treg cells revealed that, despite markedly increased *Areg* transcripts in *Foxp3*<sup>YFP<sup>Cre</sup> compared with *Foxp3*<sup>YFP<sup>Cre</sup>*Notch4* $\Delta\Delta$  Treg cells following poly(I:C) treatment (Figure 6A), amphiregulin protein expression failed to increase in Treg cells and BAL fluid of *Foxp3*<sup>YFP<sup>Cre</sup> mice. However, it was increased markedly in lung Treg cells and BAL fluid of *Foxp3*<sup>YFP<sup>Cre</sup>*Notch4* $\Delta\Delta$  mice and in *Foxp3*<sup>YFP<sup>Cre</sup> mice treated with an anti-Notch4 mAb (Figures 6A–6C). In contrast, amphiregulin expression in lung tissue Tef cells was unaffected by Notch4 antagonism (Figure 6B). Similar results were also found in the H1N1 infection model (Figures 6D and 6E). Consistent with these results, amphiregulin expression was found to be differentially enriched in Notch4<sup>+</sup> versus Notch4<sup>-</sup> lung Treg cell in poly(I:C)-treated mice (Figure 6F). Similar results were also found in lung Treg cells of influenza H1N1 virus-infected mice (data not shown).</sup></sup></sup></sup></sup>

Induction of amphiregulin expression in lung Treg cells is mediated primarily by the action of IL-18 with an ancillary effect by IL-33 (Arpaia et al., 2015). We examined the expression of IL-18R $\alpha$ , IL-6R $\alpha$ , and IL-33R on lung Treg cells in sham-infected versus

H1N1-infected mice, the latter without or with anti-Notch4 mAb therapy. The results showed that expression of IL-18R $\alpha$  on Treg cells declined upon H1N1 infection but recovered upon anti-Notch4 mAb treatment. In contrast, IL-18R $\alpha$  expression on lung tissue Tef cells was unaffected by anti-Notch4 mAb treatment (Figure 6G). Expression of IL-33R on lung Treg cells was unchanged by anti-Notch4 mAb treatment, whereas that of IL-6R $\alpha$  was increased by poly(I:C) treatment (Figure 6G). Further analysis revealed that most of the amphiregulin-expressing Treg cells strongly expressed IL-18R $\alpha$  and, to a lesser extent, IL-33R but virtually no IL-6R $\alpha$  (Figure 6H). The role of Notch4 in modulating IL-18-induced amphiregulin was analyzed in *in vitro* experiments employing lung Treg cells isolated from poly(I:C)-treated mice. Although amphiregulin expression in these Treg cells was induced minimally by IL-18 treatment, it was increased upon co-treatment with the anti-Notch4 mAb (Figure 6I). These results suggest that Notch4 inhibits amphiregulin expression in Treg cells at least in part by antagonizing its upregulation by IL-18.

To establish the role of amphiregulin in protection against lung inflammation induced by Notch4 antagonism, and in light of previous studies demonstrating a protective effect of amphiregulin treatment in respiratory infections (Jamieson et al., 2013), we examined the capacity of recombinant amphiregulin therapy to



**Figure 5. Notch4 deficiency reprograms the lung Treg cell transcriptome of poly(I:C)-treated mice**


(A–C) Volcano plot (A), heatmap (B), and pathway analysis (C) of gene transcripts of lung Treg cells isolated from *Foxp3*<sup>YFP<sup>Cre</sup></sup> and *Foxp3*<sup>YFP<sup>Cre</sup></sup>*Notch4*<sup>Δ/Δ</sup> mice treated with poly(I:C) (n = 4 and n = 5, respectively). (D) Flow cytometry histograms and graphical representation of lung tissue Treg cell expression of CD25, Helios, CTLA4, ICOS, and OX40 in *Foxp3*<sup>YFP<sup>Cre</sup></sup> and *Foxp3*<sup>YFP<sup>Cre</sup></sup>*Notch4*<sup>Δ/Δ</sup> mice sampled on day 7 after poly(I:C) treatment (n = 5 for each time point). (E–H) Flow cytometry analysis (E and G) and graphical representation (F and H) of Helios expression in *Foxp3*<sup>+</sup>*Notch4*<sup>+</sup> and *Foxp3*<sup>+</sup>*Notch4*<sup>-</sup> lung tissue Treg cells in *Foxp3*<sup>YFP<sup>Cre</sup></sup> mice sampled at the indicated dates after poly(I:C) treatment (n = 5 for each time point). Each symbol represents one mouse. Numbers in flow plots indicate percentages. Error bars indicate SEM. Statistical tests: pairwise comparisons of differential gene expression were computed using DESeq2 (A–C); Student’s unpaired two-tailed t test (D) and two-way ANOVA with Sidak’s post hoc analysis (F and H). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

rescue poly(I:C)-induced lung inflammation. Treatment of *Foxp3*<sup>YFP<sup>Cre</sup></sup> mice with recombinant amphiregulin largely abrogated the weight loss and the inflammatory responses induced by poly(I:C) treatment in association with restoration of intact epithelial barrier function (Figures 7A–7D). Recombinant amphiregulin also reversed skewing of lung macrophages toward an M1 phenotype upon their *in vitro* treatment with poly(I:C) (Figure S6D), mirroring the same effect of *Foxp3*<sup>YFP<sup>Cre</sup></sup>*Notch4*<sup>Δ/Δ</sup> Treg cells (Figure 2J).

Reciprocally, we analyzed the effect of co-treatment with an amphiregulin peptide spanning the amino-terminal heparin binding domain, which is necessary for amphiregulin activation of the epidermal growth factor receptor (EGFR) (Johnson and Wong, 1994), on the protective effects of Notch4 antagonism. The peptide was validated to competitively inhibit amphiregulin activation of EGFR, as measured by the latter’s tyrosine autophosphorylation (Figure S6C). The results showed that the amphiregulin-blocking peptide abrogated

the protective effects of anti-Notch4 mAb treatment or Treg cell-specific *Notch4* deletion in poly(I:C)-induced lung injury, resulting in exacerbated weight loss, tissue inflammation, neutrophil infiltration, and M1 macrophage skewing (Figures 7E–7I). These results were reproduced in experiments utilizing a similarly validated neutralizing anti-amphiregulin mAb (Figure S6E), which also abrogated the protection imparted by Treg cell-specific Notch4 deficiency against poly(I:C)-induced weight loss, lung tissue neutrophil infiltration, and increased M1 versus M2 macrophage skewing (Figure S6E). The anti-amphiregulin mAb co-treatment also reversed restoration by Notch4 deficiency of airway epithelial barrier integrity, as measured by increased leakage of high-molecular-weight dextran instilled in the airways into the blood stream (Figure S6F).

Consistent with the above results, analysis of the sera of subjects with COVID-19 revealed increased amphiregulin concentrations in subjects with mild disease compared with




**Figure 6. Notch4 inhibition promotes an amphiregulin-dependent immunoregulatory program**  
 (A) Flow cytometry analysis of amphiregulin expression in Treg cells from the lungs of *Foxp3<sup>YFPCre</sup>* and *Foxp3<sup>YFPCre</sup>Notch4<sup>Δ/Δ</sup>* mice sham treated or treated with poly(I:C) alone or together with an anti-Notch4 mAb, as indicated.  
 (B) Graphical representation of amphiregulin expression in lung tissue Treg and Teff cells.  
 (C) BAL fluid amphiregulin concentrations.  
 (D) Amphiregulin expression in lung tissue Treg and Teff cells of *Foxp3<sup>YFPCre</sup>* and *Foxp3<sup>YFPCre</sup>Notch4<sup>Δ/Δ</sup>* mice sham treated or infected with H1N1 influenza virus alone or together with an anti-Notch4 mAb, as indicated.  
 (E) BAL fluid amphiregulin concentrations.  
 (F) Flow cytometric analysis and graphical representation of H1N1 amphiregulin expression in Notch4<sup>+</sup> or Notch4<sup>-</sup> Treg cells from the lungs of *Foxp3<sup>YFPCre</sup>* mice treated with PBS or poly(I:C) at the indicated time points.  
 (G and H) Flow cytometry analysis and graphical representation of IL18Rα, IL6Rα, and ST2 expression in total (G) or amphiregulin<sup>+</sup> (H) Treg cells from the lungs of PBS- or poly(I:C)-treated *Foxp3<sup>YFPCre</sup>* mice with an isotype control or an anti-Notch4 mAb, as indicated.  
 (I) *In vitro* induction of amphiregulin expression in Treg cell from the lungs or spleens of poly(I:C)- or PBS-treated *Foxp3<sup>YFPCre</sup>* mice. Each symbol represents one mouse (n = 5–8 per group). Numbers in flow plots indicate percentages. Error bars indicate SEM. Statistical tests: one-way ANOVA with Dunnett's post hoc analysis (B–D, F, and G) and two-way ANOVA with Sidak's post hoc analysis (E and H). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

those of healthy controls, which declined in the sera of individuals with moderate and severe disease in a manner inversely proportional to Notch4 expression (Figure 7J). This inverse correlation between amphiregulin and Notch4 was particularly pronounced when comparing Notch4 and amphiregulin expression specifically in circulating Treg cells (Figure 7K). In contrast, there was no correlation between Notch4 and amphiregulin expression on circulating Teff cells (Figure 7K). Overall, these results are consistent with suppression of amphiregulin production by Treg cells as a key mechanism of Notch4 inhibitory function in viral infections.

## DISCUSSION

In this study, we addressed the role of a tissue-specific immunoregulatory mechanism involving inducible Notch4 expression on Treg cells in mediating severe lung tissue inflammation in COVID-19 and related viral infections. We found that Notch4 was increased on circulating Treg cells of individuals with COVID-19 as a function of disease severity and associated with heightened mortality, indicating that this mechanism is operative in SARS-CoV-2 infection and may be critically involved in the pathogenesis of acute respiratory failure in this disorder. Furthermore, by employing conventional and humanized



**Figure 7. Lung protection by Notch4 antagonism is amphiregulin dependent**

(A) Weight index and peak weight loss of *Foxp3*<sup>YFP<sup>Cre</sup></sup> mice sham treated or treated with poly(I:C) alone or together with recombinant amphiregulin. (B) Hematoxylin and eosin-stained sections and inflammation score of lung tissue isolated from the indicated mouse groups (200× magnification). (C) Serum TRITC dextran in poly(I:C) + recombinant amphiregulin-treated *Foxp3*<sup>YFP<sup>Cre</sup></sup> mice 1 h after intratracheal instillation. (D) BAL fluid concentration of IL-6. (E) Weight index and peak weight loss of *Foxp3*<sup>YFP<sup>Cre</sup></sup> and *Foxp3*<sup>YFP<sup>Cre</sup></sup> *Notch4*<sup>Δ/Δ</sup> mice sham treated or treated with poly(I:C), anti-Notch4 mAb, and/or amphiregulin-blocking peptide (bp), as indicated. (F) Hematoxylin and eosin-stained lung sections (200× magnification). (G) Inflammation scores (n = 5 per group). (H and I) Lung neutrophils (H) and M1 and M2 macrophages (I). (J) Left panel: serum amphiregulin concentrations in healthy control subjects and COVID-19 subject groups (control subjects, n = 17; mild disease, n = 20; moderate disease, n = 49; severe disease, n = 32). Right panel: Pearson correlation of Treg cell Notch4 expression and serum amphiregulin concentration in affected and control subjects (n = 99). (K) Pearson correlation of Notch4 and amphiregulin expression in Treg cells (right panel) and Teff cells (left panel) of individuals with COVID-19 (n = 39). Each symbol represents one mouse (n = 5–10 per group). Numbers in flow plots indicate percentages. Error bars indicate SEM. Statistical tests: one-way ANOVA with Dunnett's post hoc analysis (B–E and G–J) and two-way ANOVA with Sidak's post hoc analysis (A and E). \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

immune system mouse models of respiratory viral infections, we found that the evolution of severe viral lung inflammation was contingent on induction of Notch4 on lung Treg cells, which acted as a molecular switch to alter their regulatory and tissue

repair activities. Thus, Notch4 emerges as a critical regulator of disease severity in different respiratory viral infections.

Notch4 was increased on tissue Treg cells very early in lung inflammation and acted to promote the innate immune response

at a time when adaptive immunity had not yet been mobilized effectively. In particular, the downstream mechanisms by which Notch4 promoted innate immune cell activation in viral infection were different from those involved in promoting the  $T_H2$  and  $T_H17$  cell-adaptive immune responses in asthma: the Wnt and Hippo pathways, respectively (Geng et al., 2017; Harb et al., 2020). Thus, Treg cell-specific deletion of *Yap1* and *Wwtr1*, encoding the Hippo pathway mediators Yap and Taz, or *Ctnnb1*, encoding the Wnt pathway effector protein  $\beta$ -catenin, showed little effect on disease induced by poly(I:C) treatment. This bifurcation in the mechanisms by which Notch4 promotes innate versus adaptive immunity points to distinct functions served by this pathway in the respective immune responses. In the context of an acute virus-mediated injury, Notch4 allows evolution of an innate immune response instigated by lung epithelium-derived danger signals that is unencumbered by tonic Treg cell suppression (Whitsett and Alenghat, 2015), consistent with the previously noted role of Treg cells in coordinating early protective immunity to viral infection (Lund et al., 2008). This physiological function of Notch4 becomes detrimental in the context of severe respiratory viral infections, resulting in uncontrolled pathological activation of innate immunity, leading to damaging lung tissue injury.

Analysis of Notch4 expression on Treg cells in the context of respiratory viral infection revealed its restriction to lung tissue Treg cells, suggesting a lung tissue origin of circulating Notch4<sup>+</sup> Treg cells in individuals with COVID-19. Induction of Notch4 on lung Treg cells was in part IL-6 dependent, as evidenced by *in vitro* studies showing that co-treatment of lung but not splenic Treg cells with IL-6 and poly(I:C) increased Notch4 expression. These results are consistent with partial suppression of poly(I:C)-induced Notch4 expression and tissue inflammation upon Treg cell-specific deletion of *Il6ra*. They are also consistent with the positive correlation of increased Notch4 expression in individuals with COVID-19 with serum IL-6 concentrations. Notwithstanding these findings, Notch4 but not IL-6 predicted mortality in the affected population. Direct comparison of genetic and functional interventions that target Notch4 versus IL-6R pathways revealed the superiority of the former approach in mediating protection against poly(I:C) and influenza H1N1 virus-induced lung injury. This difference may reflect previously noted additional positive functions of IL-6 in protecting against severe respiratory viral infections, separate from its role in Notch4 induction (Dienz et al., 2012; Pyle et al., 2017; Yang et al., 2017).

A key mechanism by which Notch4 impairs lung tissue Treg cell function involved amphiregulin, whose expression is enriched in tissue-resident Treg cells, especially under conditions of active tissue repair (Arpaia et al., 2015; Burzyn et al., 2013; Schiering et al., 2014; Zaiss et al., 2013, 2015). Amphiregulin protein expression was increased markedly in poly(I:C)-treated and H1N1 influenza virus-infected mice upon Treg cell-specific *Notch4* deletion or treatment with an anti-Notch4 mAb. The protective function of Notch4 antagonism in viral lung injury was reproduced by treatment with recombinant amphiregulin and abrogated by co-treatment with an amphiregulin-blocking peptide or neutralizing antibody. Amphiregulin may thus serve as a key effector mechanism by which lung tissue Treg cells suppress danger signals emanating from the epithelium and other innate immune cells, including macrophages. A previous study by

Arpaia et al. (2015) has shown that Treg cells are the predominant source of amphiregulin in the course of H1N1 infection in the lungs. Furthermore, amphiregulin expression specifically in Treg cells is critical for lung tissue repair in the context of H1N1 infection, highlighting the privileged role of Treg cell-derived amphiregulin in this process (Arpaia et al., 2015). Amphiregulin expression in Treg cells is induced primarily by IL-18 and secondarily by IL-33 (Arpaia et al., 2015). Our study demonstrated that Notch4 inhibits the capacity of IL-18 to upregulate amphiregulin expression in lung Treg cells, providing a mechanism for suppression of amphiregulin protein expression by Notch4. Amphiregulin mobilization upon Notch4 antagonism would then allow recovery from virus-induced lung injury.

Our results identify the Notch4-amphiregulin nexus as a putative target of therapy in viral respiratory infections, including SAR-CoV-2 and influenza. The remarkable capacity of anti-Notch4 mAb therapy to abrogate poly(I:C) and H1N1 influenza virus-induced disease morbidity and mortality in conventional and humanized mice makes Notch4 an attractive candidate for intervention in severe respiratory viral infections. That Notch4 also plays an essential role in promoting tissue inflammation in asthma further denotes it as a hub common to different inflammatory responses in the lungs that may serve as a target of therapy. Furthermore, the essential role of amphiregulin in mediating the therapeutic outcome of Notch4 inhibition in viral lung injury points to the amphiregulin-EGFR pathway as an additional locus of intervention. The full spectrum of Notch4-licensed diseases and the role of different downstream pathways in such disorders will require further intensive investigation.

### Limitations of study

There are limitations to this study that should be noted. The individuals with COVID-19 were part of an observational cohort of adults who were predominantly of European and Turkic ethnicities. The study was not specifically designed or powered to examine differences in Notch4 expression among affected individuals of different racial and ethnic backgrounds, nor did it extend to pediatric subjects with COVID-19 or people with other lower respiratory viral infections. The mouse studies employed proxies of SARS-CoV2 infection, including poly(I:C) treatment and influenza virus infection. They were relatively short in duration and thus do not explore additional immune-regulatory mechanisms that may be operative in long-term sequelae of COVID-19. These limitations highlight the urgent task of elucidating the full range of tissue-inflammatory licensing mechanisms operative in COVID-19 and related viral infections as a requisite step for designing precision therapies to restore immune tolerance and effective tissue repair in these disorders.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability

● EXPERIMENTAL MODEL AND SUBJECT DETAILS

- Human subjects
- Study approval
- Mice

● METHOD DETAILS

- Regulatory T cell co-cultures with macrophages
- *In vitro* Macrophages–Amphiregulin co-cultures
- Mouse anti-human Notch4 monoclonal antibody generation
- Isolation of Human peripheral blood mononuclear cells (PBMCs)
- IL-6 and Amphiregulin ELISA
- Cytokine measurements
- Polyinosinic-polycytidylic acid (Poly I:C) mouse model
- H1N1 influenza A virus preparation
- H1N1 Influenza A viral infection model
- Humanized mice H1N1 viral infection
- Viral Load
- Measurement of airway functional responses
- Lung histopathology staining
- Flow cytometric analysis of mouse and human cells
- M1 and M2 gating strategy
- Transcriptome Profiling

● QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.immuni.2021.04.002>.

ACKNOWLEDGMENTS

We thank Jacob Vieira, Hui-Yu Sui, and Naci Senkal for data collection and entry. This work was supported by National Institutes of Health grants R01 AI115699, R01 AI065617, and R01 AI06561720S1 (to T.A.C.) and 1R01AI121066, 1R01DK115217, and NIAID-DAIT-NIHAI201700100 (to I.Z.); German Research Society grant HA 8465/1-1 (to H.H.); and Istanbul University BAP Project TSG2020-36834 (to G.D.). I.Z. holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund. T.A.C. is the recipient of a grant from Digitalis Ventures.

AUTHOR CONTRIBUTIONS

H.H., M.B., P.S.L., R.D.P., and T.A.C. conceived the project and designed experiments. H.H., M.B., P.S.L., P.C., J.W.G., Q.C., J.F., G.D.Z., N.P., S.K., A.B., S.G., M.Y.G., F.B.O., E.A.C., Z.W., Y.C., E.S.-V., and L.-M.C. performed experiments. I.Z., H.P., G.D., R.D.P., and T.A.C. supervised the experimental studies. P.S.L., G.D., and R.D.P. supervised subject recruitment and sample collection at the respective centers. X.G.Y., J.Z.L., and L.B. provided additional samples. P.S.L., L.M., G.F., A.K., and M.K. collected and analyzed clinical data. K.S.-A. analyzed the RNA-seq data. P.S.L., R.D.P., G.D., E.C., X.G.Y., and J.Z.L. obtained institutional review board approval at the respective centers. H.H., M.B., and T.A.C. wrote the manuscript.

DECLARATION OF INTERESTS

T.A.C., H.H., M.B., P.S.L., P.C., and R.D.P. are inventors on provisional patent application US 63/038,186 titled “Methods and Compositions for treating coronavirus infectious disease.” H.H. and T.A.C. are co-founders of and hold equity in Alcea Therapeutics.

Received: October 21, 2020

Revised: February 2, 2021

Accepted: April 2, 2021

Published: April 28, 2021

REFERENCES

- Arpaia, N., Green, J.A., Moltedo, B., Arvey, A., Hemmers, S., Yuan, S., Treuting, P.M., and Rudensky, A.Y. (2015). A Distinct Function of Regulatory T Cells in Tissue Protection. *Cell* 162, 1078–1089.
- Berlin, D.A., Gulick, R.M., and Martinez, F.J. (2020). Severe Covid-19. *N. Engl. J. Med.* 383, 2451–2460.
- Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhl, S., Hoagland, D., Møller, R., Jordan, T.X., Oishi, K., Panis, M., Sachs, D., et al. (2020). Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 181, 1036–1045.e9.
- Broggi, A., Ghosh, S., Sposito, B., Spreafico, R., Balzarini, F., Lo Cascio, A., Clementi, N., De Santis, M., Mancini, N., Granucci, F., and Zanoni, I. (2020). Type III interferons disrupt the lung epithelial barrier upon viral recognition. *Science* 369, 706–712.
- Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J.L., Cerletti, M., Jang, Y., Sefik, E., Tan, T.G., Wagers, A.J., Benoist, C., and Mathis, D. (2013). A special population of regulatory T cells potentiates muscle repair. *Cell* 155, 1282–1295.
- Charbonnier, L.M., Wang, S., Georgiev, P., Sefik, E., and Chatila, T.A. (2015). Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. *Nat. Immunol.* 16, 1162–1173.
- Cho, J.L., Roche, M.I., Sandall, B., Brass, A.L., Seed, B., Xavier, R.J., and Medoff, B.D. (2012). Enhanced Tim3 activity improves survival after influenza infection. *J. Immunol.* 189, 2879–2889.
- Copaescu, A., Smibert, O., Gibson, A., Phillips, E.J., and Trubiano, J.A. (2020). The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *J. Allergy Clin. Immunol.* 146, 518–534.e1.
- Cucinotta, D., and Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. *Acta Biomed.* 91, 157–160.
- Del Valle, D.M., Kim-Schulze, S., Huang, H.H., Beckmann, N.D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T.H., Madduri, D., Stock, A., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat. Med.* 26, 1636–1643.
- Dienz, O., Rud, J.G., Eaton, S.M., Lanthier, P.A., Burg, E., Drew, A., Bunn, J., Suratt, B.T., Haynes, L., and Rincon, M. (2012). Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. *Mucosal Immunol.* 5, 258–266.
- Esty, B., Harb, H., Bartnikas, L.M., Charbonnier, L.M., Massoud, A.H., Leon-Astudillo, C., Visner, G., Subramaniam, M., Phipatanakul, W., and Chatila, T.A. (2019). Treatment of severe persistent asthma with IL-6 receptor blockade. *J. Allergy Clin. Immunol. Pract.* 7, 1639–1642.e4.
- Geng, J., Yu, S., Zhao, H., Sun, X., Li, X., Wang, P., Xiong, X., Hong, L., Xie, C., Gao, J., et al. (2017). The transcriptional coactivator TAZ regulates reciprocal differentiation of T<sub>H</sub>17 cells and T<sub>reg</sub> cells. *Nat. Immunol.* 18, 800–812.
- Glenn, J.D., Smith, M.D., Xue, P., Chan-Li, Y., Collins, S., Calabresi, P.A., Horton, M.R., and Whartenby, K.A. (2017). CNS-targeted autoimmunity leads to increased influenza mortality in mice. *J. Exp. Med.* 214, 297–307.
- Hadjadi, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020). Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 369, 718–724.
- Han, H., Tanigaki, K., Yamamoto, N., Kuroda, K., Yoshimoto, M., Nakahata, T., Ikuta, K., and Honjo, T. (2002). Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. *Int. Immunol.* 14, 637–645.
- Harb, H., Stephen-Victor, E., Crestani, E., Benamar, M., Massoud, A., Cui, Y., Charbonnier, L.M., Arbag, S., Baris, S., Cunningham, A., et al. (2020). A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma. *Nat. Immunol.* 21, 1359–1370.
- Henderson, L.A., Canna, S.W., Schuler, G.S., Volpi, S., Lee, P.Y., Kernan, K.F., Caricchio, R., Mahmud, S., Hazen, M.M., Halyabar, O., et al. (2020). On the Alert for Cytokine Storm: Immunopathology in COVID-19. *Arthritis Rheumatol.* 72, 1059–1063.

- Hermine, O., Mariette, X., Tharaux, P.L., Resche-Rigon, M., Porcher, R., and Ravaud, P.; CORIMUNO-19 Collaborative Group (2021). Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Intern. Med.* **181**, 32–40.
- Iwasaki, A., and Pillai, P.S. (2014). Innate immunity to influenza virus infection. *Nat. Rev. Immunol.* **14**, 315–328.
- Jamieson, A.M., Pasman, L., Yu, S., Gamradt, P., Homer, R.J., Decker, T., and Medzhitov, R. (2013). Role of tissue protection in lethal respiratory viral-bacterial coinfection. *Science* **340**, 1230–1234.
- Johnson, G.R., and Wong, L. (1994). Heparan sulfate is essential to amphiregulin-induced mitogenic signaling by the epidermal growth factor receptor. *J. Biol. Chem.* **269**, 27149–27154.
- Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., et al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**, 101–105.
- Kearney, J.F., Radbruch, A., Liesegang, B., and Rajewsky, K. (1979). A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. *J. Immunol.* **123**, 1548–1550.
- Köhler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* **256**, 495–497.
- Lowther, D.E., Goods, B.A., Lucca, L.E., Lerner, B.A., Raddassi, K., van Dijk, D., Hernandez, A.L., Duan, X., Gunel, M., Coric, V., et al. (2016). PD-1 marks dysfunctional regulatory T cells in malignant gliomas. *JCI Insight* **1**, e85935.
- Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson, M.K., Mao, T., Oh, J.E., Israelow, B., et al.; Yale IMPACT Team (2020). Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* **584**, 463–469.
- Lund, J.M., Hsing, L., Pham, T.T., and Rudensky, A.Y. (2008). Coordination of early protective immunity to viral infection by regulatory T cells. *Science* **320**, 1220–1224.
- McCright, B., Lozier, J., and Gridley, T. (2006). Generation of new Notch2 mutant alleles. *Genesis* **44**, 29–33.
- McFarland-Mancini, M.M., Funk, H.M., Paluch, A.M., Zhou, M., Giridhar, P.V., Mercer, C.A., Kozma, S.C., and Drew, A.F. (2010). Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. *J. Immunol.* **184**, 7219–7228.
- Messerschmidt, D., de Vries, W.N., Lorthongpanich, C., Balu, S., Solter, D., and Knowles, B.B. (2016).  $\beta$ -catenin-mediated adhesion is required for successful preimplantation mouse embryo development. *Development* **143**, 1993–1999.
- Molledo, B., Li, W., Yount, J.S., and Moran, T.M. (2011). Unique type I interferon responses determine the functional fate of migratory lung dendritic cells during influenza virus infection. *PLoS Pathog.* **7**, e1002345.
- Ostroukhova, M., Qi, Z., Oriss, T.B., Dixon-McCarthy, B., Ray, P., and Ray, A. (2006). Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF- $\beta$ . *J. Clin. Invest.* **116**, 996–1004.
- Païro-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A.D., Rawlik, K., Pasko, D., Walker, S., Parkinson, N., Fourman, M.H., Russell, C.D., et al.; GenOMICC Investigators; ISARIC4C Investigators; COVID-19 Human Genetics Initiative; 23andMe Investigators; BRACOVIG Investigators; GenCOVID Investigators (2021). Genetic mechanisms of critical illness in COVID-19. *Nature* **591**, 92–98.
- Perumalsamy, L.R., Marcel, N., Kulkarni, S., Radtke, F., and Sarin, A. (2012). Distinct spatial and molecular features of notch pathway assembly in regulatory T cells. *Sci. Signal.* **5**, ra53.
- Pyle, C.J., Uwadiae, F.I., Swieboda, D.P., and Harker, J.A. (2017). Early IL-6 signalling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology. *PLoS Pathog.* **13**, e1006640.
- Reginensi, A., Scott, R.P., Gregorieff, A., Bagherie-Lachidan, M., Chung, C., Lim, D.S., Pawson, T., Wrana, J., and McNeill, H. (2013). Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development. *PLoS Genet.* **9**, e1003380.
- Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, J.M., McGinn, T., Davidson, K.W., Barnaby, D.P., Becker, L.B., Chelico, J.D., Cohen, S.L., et al.; the Northwell COVID-19 Research Consortium (2020). Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **323**, 2052–2059.
- Rosas, I.O., Brau, N., Waters, M., Go, R.C., Hunter, B.D., Bhagani, S., Skiest, D., Aziz, M.S., Cooper, N., Douglas, I.S., et al. (2021). Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *N. Engl. J. Med.* Published online February 25, 2021. <https://doi.org/10.1056/NEJMoa2028700>.
- Rubtsov, Y.P., Rasmussen, J.P., Chi, E.Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W.R., Jr., et al. (2008). Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity* **28**, 546–558.
- Salama, C., Han, J., Yau, L., Reiss, W.G., Kramer, B., Neidhart, J.D., Criner, G.J., Kaplan-Lewis, E., Baden, R., Pandit, L., et al. (2021). Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N. Engl. J. Med.* **384**, 20–30.
- Salvarani, C., Dolci, G., Massari, M., Merlo, D.F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al.; RCT-TCZ-COVID-19 Study Group (2021). Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. *JAMA Intern. Med.* **181**, 24–31.
- Schiering, C., Krausgruber, T., Chomka, A., Fröhlich, A., Adelmann, K., Wohlfert, E.A., Pott, J., Griseri, T., Bollrath, J., Hegazy, A.N., et al. (2014). The alarmin IL-33 promotes regulatory T-cell function in the intestine. *Nature* **513**, 564–568.
- Shi, S., and Stanley, P. (2003). Protein O-fucosyltransferase 1 is an essential component of Notch signaling pathways. *Proc. Natl. Acad. Sci. USA* **100**, 5234–5239.
- Tachdjian, R., Mathias, C., Al Khatib, S., Bryce, P.J., Kim, H.S., Blaeser, F., O'Connor, B.D., Rzymkiewicz, D., Chen, A., Holtzman, M.J., et al. (2009). Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma. *J. Exp. Med.* **206**, 2191–2204.
- The REMAP-CAP Investigators (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N. Engl. J. Med.* Published online February 25, 2021. <https://doi.org/10.1056/NEJMoa2100433>.
- Thornton, A.M., Lu, J., Korty, P.E., Kim, Y.C., Martens, C., Sun, P.D., and Shevach, E.M. (2019). Helios<sup>+</sup> and Helios<sup>-</sup> Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires. *Eur. J. Immunol.* **49**, 398–412.
- Toniati, P., Piva, S., Cattalini, M., Garrafa, E., Regola, F., Castelli, F., Franceschini, F., Airò, P., Bazzani, C., Beindorf, E.A., et al. (2020). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun. Rev.* **19**, 102568.
- Vabret, N., Britton, G.J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M.D., et al. (2020). Immunology of COVID-19: current state of the science. *Immunity* **52**, 910–941.
- Veiga, V.C., Prats, J.A.G.G., Farias, D.L.C., Rosa, R.G., Dourado, L.K., Zampieri, F.G., Machado, F.R., Lopes, R.D., Berwanger, O., Azevedo, L.C.P., et al.; Coalition covid-19 Brazil VI Investigators (2021). Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. *BMJ* **372**, n84.
- Verma, M.K., Clemens, J., Burzenski, L., Sampson, S.B., Brehm, M.A., Greiner, D.L., and Shultz, L.D. (2017). A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. *J. Immunol. Methods* **446**, 47–53.
- Whitsett, J.A., and Alenghat, T. (2015). Respiratory epithelial cells orchestrate pulmonary innate immunity. *Nat. Immunol.* **16**, 27–35.
- Winkler, E.S., Bailey, A.L., Kafai, N.M., Nair, S., McCune, B.T., Yu, J., Fox, J.M., Chen, R.E., Earnest, J.T., Keeler, S.P., et al. (2020). SARS-CoV-2

infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. *Nat. Immunol.* **21**, 1327–1335.

Woodham, A.W., Zeigler, S.H., Zeyang, E.L., Kolifrath, S.C., Cheloha, R.W., Rashidian, M., Chaparro, R.J., Seidel, R.D., Garforth, S.J., Dearing, J.L., et al. (2020). In vivo detection of antigen-specific CD8(+) T cells by immunopositron emission tomography. *Nat. Methods* **17**, 1025–1032.

Xia, M., Viera-Hutchins, L., Garcia-Lloret, M., Noval Rivas, M., Wise, P., McGhee, S.A., Chatila, Z.K., Daher, N., Sioutas, C., and Chatila, T.A. (2015). Vehicular exhaust particles promote allergic airway inflammation through an aryl hydrocarbon receptor-notch signaling cascade. *J. Allergy Clin. Immunol.* **136**, 441–453.

Xia, M., Harb, H., Saffari, A., Sioutas, C., and Chatila, T.A. (2018). A Jagged 1-Notch 4 molecular switch mediates airway inflammation induced by ultrafine particles. *J. Allergy Clin. Immunol.* **142**, 1243–1256.e17.

Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. *Proc. Natl. Acad. Sci. USA* **117**, 10970–10975.

Yang, X., Klein, R., Tian, X., Cheng, H.T., Kopan, R., and Shen, J. (2004). Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. *Dev. Biol.* **269**, 81–94.

Yang, M.L., Wang, C.T., Yang, S.J., Leu, C.H., Chen, S.H., Wu, C.L., and Shiau, A.L. (2017). IL-6 ameliorates acute lung injury in influenza virus infection. *Sci. Rep.* **7**, 43829.

Zaiss, D.M., van Loosdregt, J., Gorlani, A., Bekker, C.P., Gröne, A., Sibilia, M., van Bergen en Henegouwen, P.M., Roovers, R.C., Coffey, P.J., and Sijts, A.J. (2013). Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. *Immunity* **38**, 275–284.

Zaiss, D.M.W., Gause, W.C., Osborne, L.C., and Artis, D. (2015). Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. *Immunity* **42**, 216–226.

Zhang, N., Bai, H., David, K.K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R.A., and Pan, D. (2010). The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. *Dev. Cell* **19**, 27–38.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020a). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054–1062.

Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020b). Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. *Cell Host Microbe* **27**, 883–890.e2.



STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
eBioscience Fixable Viability Dye eFluor 506 and eFluor 780	Thermo Fischer	Cat# 65-0866-18 Cat# 65-0865-14
APC-Cy7 and FITC anti-mouse CD3 Antibody	Biolegend	Cat# 100222; RRID AB_2242784 Cat# 100204; RRID AB_312661
Brilliant Violet 605 anti-mouse CD4 Antibody	Biolegend	Cat# 100451; RRID AB_2564591
Brilliant Violet 605 anti-mouse CD86 Antibody	Biolegend	Cat# 105036; RRID AB_2686973
PE anti-mouse IL-4 Antibody	Biolegend	Cat# 504104; RRID AB_315318
FOXP3 Monoclonal Antibody (FJK-16 s), eFluor 450, eBioscience	Thermo Fischer	Cat# 48-5773-82; RRID AB_1518812
PE/Cyanine7 anti-mouse IFN- $\gamma$ Antibody	Biolegend	Cat# 505825; RRID AB_1595591
IL-13 Monoclonal Antibody (eBio13A), APC-eFluor 780, eBioscience	Thermo Fischer	Cat# 47-7133-82; RRID AB_2716964
PE/Cyanine7 anti-mouse IL-17A Antibody	Biolegend	Cat# 506922I AB_2125010
APC anti-mouse IFN- $\gamma$ Antibody	Biolegend	Cat# 505810; RRID AB_315404
PE Anti-Mouse TNF	BD Biosciences	Cat# 554419; RRID AB_395380
HELIOS Monoclonal Antibody (22F6), APC-eFluor 780, eBioscience	Thermo Fischer	Cat# 47-9883-42; AB_2573998
PE/Cyanine7 anti-mouse CD11c Antibody	Biolegend	Cat# 117317; RRID AB_493569
FITC anti-mouse I-Ad Antibody	Biolegend	Cat# 115006; RRID AB_313621
Brilliant Violet 605 anti-mouse CD45 Antibody	Biolegend	Cat# 103140; RRID AB_2562342
PE anti-mouse CD152 (CTLA-4) Antibody	Biolegend	Cat# 106306; RRID AB_313255
Alexa Fluor® 647 anti-mouse CD279 (PD-1) Antibody	Biolegend	Cat# 109118; RRID AB_2566550
PerCP/Cyanine5.5 anti-mouse/human CD11b Antibody	Biolegend	Cat# 101227; RRID AB_893233
Brilliant Violet 605 anti-mouse CD4 Antibody	Biolegend	Cat# 100451; RRID AB_2564591
PE/Cyanine7 anti-mouse CD206 (MMR) Antibody	Biolegend	Cat# 141719; RRID AB_2562247
APC anti-mouse CD163 Antibody	Biolegend	Cat# 155305; RRID AB_2814059
APC/Cyanine7 anti-mouse CD68 Antibody	Biolegend	Cat# 137023; RRID AB_2616812
eFluor 450 anti-mouse CD44 Antibody	Thermo Fischer	Cat# 48-0441-82; RRID AB_1272246
APC anti-mouse CD62L Antibody	Thermo Fischer	Cat# 17-0621-82; RRID AB_469410
PE/Cyanine5 anti-mouse CD80 Antibody	Biolegend	Cat# 104711; RRID AB_313132
F4/80 Monoclonal Antibody (BM8), eFluor 450, eBioscience	Thermo Fischer	Cat# 48-4801-82; RRID AB_1548747
PerCP/Cyanine5.5 anti-mouse IL-33R $\alpha$ (IL1RL1, ST2) Antibody	Biolegend	Cat# 145311; RRID AB_2565635
FITC anti-mouse Lineage Cocktail	Biolegend	Cat# 133301
PE/Cyanine7 anti-mouse CD25 Antibody	Thermo Fischer	Cat# 25-0251-82; RRID AB_469608
APC-eFluor 780 anti-mouse HELIOS Antibody	Thermo Fischer	Cat# 47-9883-42; RRID AB_2573998
PE/Cyanine7 anti-mouse IL-17A Antibody	Biolegend	Cat# 506921; RRID AB_2125011
PE anti-mouse Ki-67 Antibody	Thermo Fischer	Cat# 12-5698-82; RRID AB_11150954
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody	Biolegend	Cat# 108405; RRID AB_313370
Brilliant Violet 605 anti-mouse CD45 Antibody	Biolegend	Cat# 103139; RRID AB_2562341
PE anti-mouse Notch 4 Antibody	Biolegend	Cat# 128407; RRID AB_1133997
CD134 (OX40) Monoclonal Antibody (OX-86), APC, eBioscience	Thermo Fischer	Cat# 17-1341-82; RRID AB_10717260

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
APC anti-mouse CD152 Antibody	Biolegend	Cat# 106309; RRID AB_2230158
CD223 (LAG-3) Monoclonal Antibody (eBioC9B7W (C9B7W)), PE, eBioscience	Thermo Fischer	Cat# 12-2231-83; RRID AB_494214
CD279 (PD-1) Monoclonal Antibody (J43), PE, eBioscience	Thermo Fischer	Cat# 12-9985-82; RRID AB_466295
<i>InVivo</i> Ab anti-mouse IL-6R	BioxCel	Cat# BE0047; RRID AB_1107588
PE anti-mouse CD339 (Jagged 1) Antibody	Biolegend	Cat# 130907; RRID AB_2561302
AREG antibody	BiorByt	orb676838
PE/Cyanine7 anti-mouse CD126 (IL-6R $\alpha$ chain) Antibody	Biolegend	Cat# 115813; RRID AB_2565574
Phospho-EGF Receptor (Tyr1068) (D7A5) XP <sup>®</sup> Rabbit mAb #3777	CST	Cat# 3777T
TruStain FcX (anti-mouse CD16/32) Antibody	Biolegend	Cat# 101319; RRID AB_1574973
PerCP/Cyanine5.5 anti-human CD4 Antibody	Biolegend	Cat# 300529; RRID AB_893328
FOXP3 Monoclonal Antibody (PCH101), eFluor 450, eBioscience	Thermo Fischer	Cat# 48-4776-42; RRID AB_1834364 Cat# 56-4716-41
HELIOS Monoclonal Antibody (22F6), APC-eFluor 780, eBioscience	Thermo Fischer	Cat# 47-9883-42; RRID AB_2573998
BB515 Mouse Anti-Human Notch1	BD Biosciences	Cat# 566023
BV605 Mouse Anti-Human Notch2	BD Biosciences	Cat# 742291
BV421 Mouse Anti-Human Notch3	BD Biosciences	Cat# 744828
PE Mouse Anti-Human Notch4	BD Biosciences	Cat# 563269
YAP (D8H1X) XP <sup>®</sup> Rabbit mAb (Alexa Fluor <sup>®</sup> 488 Conjugate)	CST	Cat# 14729S
Human/Mouse/Rat beta-Catenin Alexa Fluor <sup>®</sup> 405-conjugated Antibody	R&D	Cat# IC13292V
PE/Cyanine7 anti-human CD127 (IL-7R $\alpha$ ) Antibody	Biolegend	Cat# 351320; RRID AB_10897098
CD25 Monoclonal Antibody (BC96), Alexa-Fluor 647, eBioscience	Thermo Fischer	Cat# 51025941
APC/Cyanine7 anti-human CD3 Antibody	Biolegend	Cat# 300317; RRID AB_314053
Brilliant Violet 605 anti-human IL-4 Antibody	Biolegend	Cat# 500827; RRID AB_2562311
PerCP-Cyanine5.5 anti-human CD4 Antibody	Thermo Fischer	Cat# 45-0049-42; RRID AB_1518744
PerCP/Cyanine5.5 anti-human IL-13 Antibody	Biolegend	Cat# 501912; RRID AB_2124283
Brilliant Violet 605 anti-human CD194 (CCR4) Antibody	Biolegend	Cat# 359417; RRID AB_2562482
APC anti-human CD183 (CXCR3) Antibody	Biolegend	Cat# 353707; RRID AB_10962949
FITC anti-human CD294 (CRTH2) Antibody	Biolegend	Cat# 350107; RRID AB_11204250
PE-Cy7 Mouse Anti-Human IFN- $\gamma$	BD Biosciences	Cat# 560741
Brilliant Violet 510 anti-human CD196 (CCR6) Antibody	Biolegend	Cat# 353423; RRID AB_2561936
<i>InVivo</i> MAb anti-mouse Notch4	BioxCel	Cat# BE0129; RRID AB_10948996
<b>Critical commercial assays</b>		
recombinant Amphiregulin	R&D	Cat# 989-AR-100/CF
Dynabeads Mouse T-Activator CD3/CD28	Thermo Fischer	Cat# 11452D
Poly(I:C) HMW	Invivogen	Cat# tlrl-pic-5
recombinant IL-6	Peptotech	Cat# 500-P56
recombinant IL-33	Peptotech	Cat# 210-33
recombinant IL-18	R&D	Cat# 9139-IL-010/CF
Notch4-His protein	Sino-Biologicals	Cat# 11869-H08B
complete Freund's adjuvant	Sigma Chemical	Cat# F5881-10ML
Mouse IL-6 Quantikine ELISA Kit	R&D	Cat# M6000B

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Human IL-6 Quantikine ELISA Kit	R&D	Cat# D6050
Human Amphiregulin Quantikine ELISA Kit	R&D	Cat# DAR00
Mouse Amphiregulin Quantikine ELISA Kit	R&D	Cat# DY989
LEGENDplex Human Anti-Virus Response Panel	Biologend	Cat# 740349
LEGENDplex Mouse Inflammation Panel	Biologend	Cat# 740150
Mouse Oncostatin M (OSM) Quantikine ELISA Kit	R&D	Cat# MSM00
Mouse LIF Quantikine ELISA Kit	R&D	Cat# MLF00
Mouse LIX Quantikine ELISA Kit	R&D	Cat# MX000
Mouse Amphiregulin Antibody	R&D	Cat# AF989
Normal Goat IgG Control	R&D	Cat# AB-108-C
AREG blocking peptide	Mybiosource	Cat# MBS3224924
RNAeasy mini kit	QIAGEN	Cat# 74104
SuperScript III First-Strand Synthesis System	Thermo Fischer	Cat# 18080051
TRITC-Dextran	Sigma Chemical	Cat# 42874-1G

**Experimental models: Organisms/strains**

Il6rfl/fl (B6;SJL-Il6ratm1.1Drew/J)	Jax Laboratory	Stock No: 012944
Notch1fl/fl (B6.129X1-Notch1tm2Rko/Grid/J)	Jax Laboratory	Stock No: 007181
Notch2fl/fl (B6.129S-Notch2tm3Grid/J)	Jax Laboratory	Stock No: 010525
Notch3fl/fl	In this paper	N/A
Wwtr1fl/fl (B6.129(Cg)-Wwtr1tm1Hmc/J)	Jax Laboratory	Stock No: 032669
Yap1fl/fl (B6.129P2(Cg)-Yap1tm1.1Dupa/J)	Jax Laboratory	Stock No: 032192
NOD-Prkdc <sup>scid</sup> Il2rg <sup>tm1wjl</sup> /Sz (NSG)	Jax Laboratory	Stock No: 005557
(Ctnnb1 <sup>fl/fl</sup> ) (B6(Cg)-Ctnnb1 <sup>tm1Kmw</sup> /J)	Jax Laboratory	Stock No: 022775
Notch4tm1c(NCOM)Mfgc	Canadian mutant mouse repository	
Rbpj1fl/fl (B6.129P2-Rbpjtm1Hon/HonRbrc)	Pamela Stanley and Tasuku Honjo,	
Foxp3 <sup>YFPcre</sup>	Jax	Stock No: 016959
Influenza A/PR/8/34 (H1N1)	Charles River	

**Deposited data**

GEO	GSE159584: A Regulatory T Cell Notch4 Switch Governs Lung Inflammation in Viral Infections
-----	--

**Software and algorithms**

GraphPad Prism 8	GraphPad Software	N/A
FlowJo 10.4.2	Tree Star	<a href="https://www.flowjo.com/solutions/flowjo/downloads">https://www.flowjo.com/solutions/flowjo/downloads</a>

**RESOURCE AVAILABILITY****Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Talal A. Chatila ([talal.chatila@childrens.harvard.edu](mailto:talal.chatila@childrens.harvard.edu))

**Materials availability**

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

**Data and code availability**

The data presented in the manuscript, including de-identified patient results, will be made available to investigators following request to the corresponding author. Any data and materials to be shared will be released via a material transfer agreement. RNA sequencing datasets have been deposited in the Gene Expression Omnibus, GSE159584: A Regulatory T Cell Notch4 Switch Governs Lung Inflammation in Viral Infections.

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Human subjects

We recruited three prospective cohorts of patients with COVID-19 from the following institutions: (1) Massachusetts General Hospital in Boston, Massachusetts, USA; (2) San Martino Hospital in Genoa, Italy; (3) Istanbul Medical Faculty Hospitals in Istanbul, Turkey. The patient demographics are shown in [Table S1](#). Inclusion criterion included a clinical syndrome consistent with COVID-19 disease and a positive SARS-CoV-2 test from a nasal swab based on RT-PCR. Severity of illness was defined as follows: (1) Mild for patients who did not require inpatient hospitalization; (2) Moderate for patients requiring inpatient hospitalization and who did not require therapies for acute respiratory failure such as high flow oxygen (defined as a flow rate of more than 15 l per minute), non-invasive positive pressure ventilation, mechanical ventilation, and who did not require therapies for other types of organ failure such as renal replacement therapy or shock; (3) Severe for patients with organ failure requiring supportive therapies typically administered in the intensive care unit such as high flow oxygen, non-invasive positive pressure ventilation, mechanical ventilation, vasopressors, renal replacement therapy; (4) Convalescent for patients who have recovered from their acute illness and discharged from the hospital. A cohort of country-matched healthy controls were also recruited ([Table S1](#)).

Clinical data including patient characteristics, therapies received, and clinical outcomes was abstracted from the medical record into a password-protected REDCap (Research Electronic Data Capture) database. A peripheral blood draw was obtained at the time of enrollment and weekly thereafter (if available) for flow cytometry and cytokine analysis.

### Study approval

Recruitment of Boston study participants was approved by the Institutional Review Board at Massachusetts General Hospital and Boston Children's Hospital. Recruitment of Genoa study participants was approved by the Institutional Review Board at Genoa University. Recruitment of Istanbul study participants was approved by the Institutional Review Board at Istanbul University. All animal studies were reviewed and approved by the Boston Children's Hospital office of Animal Care Resources and Massachusetts General Hospital office of Animal Care Resources.

### Mice

The following mouse strains were obtained from the JAX Laboratories: *Foxp3*<sup>YFPCre</sup> (B6.129(Cg)-*Foxp3*<sup>tm4(YFP/cre)Ayr/J</sup>) ([Rubtsov et al., 2008](#)), *Il6*<sup>fl/fl</sup> (B6;SJL-*Il6*<sup>tm1.1Drew/J</sup>) ([McFarland-Mancini et al., 2010](#)), *Notch1*<sup>fl/fl</sup> (B6.129X1-*Notch1*<sup>tm2Rko/Grid/J</sup>) ([Yang et al., 2004](#)), *Notch2*<sup>fl/fl</sup> (B6.129S-*Notch2*<sup>tm3Grid/J</sup>) ([McCright et al., 2006](#)), *Notch3*<sup>fl/fl</sup> *Wwtr1*<sup>fl/fl</sup> (B6.129(Cg)-*Wwtr1*<sup>tm1Hmc/J</sup>) and *Yap1*<sup>fl/fl</sup> (B6.129P2(Cg)-*Yap1*<sup>tm1.1Dup/J</sup>) ([Reginensi et al., 2013](#); [Zhang et al., 2010](#)), NOD-*Prkdc*<sup>scid</sup>*Il2rg*<sup>tm1wjl/Sz</sup> (NSG) ([Verma et al., 2017](#)), and (*Ctnnb1*<sup>fl/fl</sup>) (B6(Cg)-*Ctnnb1*<sup>tm1Kw/J</sup>) ([Messerschmidt et al., 2016](#)) mice. *Notch4*<sup>fl/fl</sup> (*Notch4*<sup>tm1c(NCOM)Mfgc</sup>) were obtained from the Canadian mutant mouse repository. *Rbpj1*<sup>fl/fl</sup> (B6.129P2-*Rbpj1*<sup>tm1Hon/HonRbrc</sup>) were kind gifts of Pamela Stanley and Tasuku Honjo, respectively ([Han et al., 2002](#); [Shi and Stanley, 2003](#)). *Notch3* floxed allele mice (*Notch3*<sup>fl/fl</sup>) were derived by Crispr/Cas 9 targeting with LoxP sequences inserted in introns 4 and 9 to target exons 5-9 by Cre-mediated excision.

## METHOD DETAILS

### Regulatory T cell co-cultures with macrophages

Macrophages cells were isolated from lungs of Poly I:C-treated mice. Macrophages were isolated based on CD45<sup>+</sup> F4/80<sup>+</sup> MHCII<sup>+</sup>. Macrophages were then co-cultured (at 1:1 concentration) with lungs Treg cells from *Foxp3*<sup>YFPCre</sup> or *Foxp3*<sup>YFPCre</sup>*Notch4*<sup>Δ/Δ</sup> mice Poly I:C-treated mice. Cells were treated with Poly I:C at a concentration of 10ug/ml for three days. After 72h, M1 (F4/80<sup>+</sup> MHCII<sup>+</sup> CD68<sup>+</sup> CD80<sup>+</sup>CD86<sup>+</sup>) and M2 (F4/80<sup>+</sup> MHCII<sup>+</sup> CD163<sup>+</sup> CD206<sup>+</sup>) polarization was measured by flow cytometric analysis.

### In vitro Macrophages–Amphiregulin co-cultures

Macrophages cells were isolated from the lungs of Poly I:C treated *Foxp3*<sup>YFPCre</sup> mice. These cells were incubated with recombinant Amphiregulin (R&D) (10 μg/ml). 72 hours later, the expression of different M1 and M2 markers were measured by flow cytometry.

### In vitro Notch4 induction

Lung and spleen Treg cells from Poly I:C or PBS-treated *Foxp3*<sup>YFPCre</sup> mice were isolated by cell sorting (Sony Sorter, MA900). Treg cells were seeded at 1 × 10<sup>4</sup> cells in 96-well plates then stimulated with CD3/CD28 Dynabeads (ThermoFisher) in presence of Poly I:C (10 μg/ml) alone or in combination with recombinant IL-6 and IL-33 (10 μg/ml; Peprotech) for 72h. Notch4 expression on *Foxp3*<sup>+</sup> Treg cells was then assessed by Flow cytometry.

### In vitro amphiregulin induction

Lung Treg cells from Poly I:C or PBS-treated *Foxp3*<sup>YFPCre</sup> mice were seeded at 1 × 10<sup>4</sup> cells then stimulated with CD3/CD28 Dynabeads with Poly I:C (10 μg/ml) either alone or in combination with recombinant IL-18 and IL-33 (R&D systems, Peprotech, respectively, 10 μg/ml) for 72h. Amphiregulin expression was then assessed by Flow cytometry.

### Mouse anti-human Notch4 monoclonal antibody generation

Notch4-deficient mice were immunized with 50 μg of recombinant Notch4-His protein (Sino-Biologicals, Wayne, PA) suspended in Dulbecco's phosphate buffered saline (PBS; GIBCO, Grand Island, NY) and emulsified with an equal volume of complete Freund's adjuvant

(Sigma Chemical Co., St. Louis, MO). Fourteen days after the initial immunization, the mice were given a booster immunization i.p. with 25  $\mu$ g of recombinant Notch4-His protein suspended in PBS and emulsified with an equal volume of incomplete Freund's adjuvant. A second booster of 25  $\mu$ g of recombinant Notch-His protein in PBS was given after another 14 days. The mice were re-boostered 2X with 25  $\mu$ g of recombinant Notch4-His protein to raise their antibody titers, then the mouse with the best titer was rested for 3 weeks from the last immunization, then boosted by intraperitoneal and subcutaneous injection of 25  $\mu$ g recombinant Notch4-His protein in PBS. Three days later the mouse was euthanized, and the spleen and lymph nodes were collected and made into a cell suspension, then washed with DMEM. The spleen/lymph node cells were counted and mixed with SP 2/0 myeloma cells (ATCC No. CRL8-006, Rockville, MD) that are incapable of secreting either heavy or light chain immunoglobulin chains (Kearney et al., 1979) using a spleen:myeloma ratio of 2:1. Cells were fused with polyethylene glycol 1450 (ATCC) in eight 96-well tissue culture plates in HAT selection medium according to standard procedures (Köhler and Milstein, 1975). Between 10 and 21 days after the fusions, hybridoma colonies became visible and culture supernatants were harvested then screened by ELISA for Notch4. Potential positive wells were expanded and re-screened against Notch1-His, Notch2-His, Notch3-His/Gst, Notch4-His and an irrelevant protein by ELISA. Hybridomas showing specificity for Notch4 alone were identified and subcloned twice by limiting dilution to obtain stable, clonal hybridomas.

### Isolation of Human peripheral blood mononuclear cells (PBMCs)

Human PBMCs were isolated from whole blood from either healthy control, mild COVID-19, moderate COVID-19 or severe COVID-19 probands via density gradient using Ficoll (GE Healthcare). PBMCs were then stored frozen in Fetal Calf Serum (FCS) (Sigma Aldrich) and 15% Dimethyl sulfoxide (DMSO) (Sigma Aldrich). The cells were later thawed for analysis of their Notch, Yap1,  $\beta$ -Catenin or different chemokine and cytokine expression by flow cytometry.

### IL-6 and Amphiregulin ELISA

Genoa patients IL-6 concentrations were measured using ELISA (R&D, USA) per manufacturer's protocol. As for Amphiregulin, Amphiregulin concentrations for the whole cohort were measured using Amphiregulin ELISA kit (R&D, USA).

### Cytokine measurements

IL-1 $\beta$ , IL-6 (For Boston and Istanbul cohorts), IL-8, IFN $\alpha$ , IFN $\beta$ , IFN $\gamma$ , IFN $\lambda$ , CXCL10 and TNF were measured using Legendplex (Biolegend) per manufacturer's protocol. Mouse cytokine were assessed using Legendplex (Biolegend) per manufacturer's protocol on BAL samples from Poly I:C treated mice (Day 7) or on BAL samples from H1N1-infected mice (Day 12). OSM, LIF and CXCL5 were also measured on the same samples using Quantikine Elisa kits (R&D systems).

### Polyinosinic-polycytidylic acid (Poly I:C) mouse model

Mice were treated intratracheally with 2.5 mg/kg of Poly I:C HMW (InvivoGen) daily for six consecutive days. The weight of the mice was recorded daily upon application of the Poly I:C. The mice were subjected to airway hyperresponsiveness at day 7, then euthanized and analyzed. For blocking amphiregulin, mice were treated with a peptide spanning amino acids 91-140 of the middle region of the human amphiregulin preproprotein (amphiregulin<sub>91-140</sub> peptide; Mybiosource). The peptide was given intratracheally at 10  $\mu$ g/ml in PBS in a final volume of 100  $\mu$ l. For the amphiregulin neutralizing antibody tests, the mice were given intraperitoneally 20  $\mu$ g of goat anti-mouse amphiregulin mAb (clone AF989; R&D systems) or isotype control mAb (clone AB-108-C; R&D systems) daily for the duration of the experiment.

### H1N1 influenza A virus preparation

Mouse-adapted H1N1 Influenza A virus (PR/8/34) was obtained from Charles River (Catalogue no. 10100374). Viral stocks were calculated to contain 40,000 infectious units (IU) per mouse and were diluted to a volume of 20  $\mu$ l/mouse in PBS. For lethal dose (LD75), the viral stocks were calculated to contain 60,000 IU per mouse and diluted to a volume of 20  $\mu$ l/mouse in PBS as well.

### H1N1 Influenza A viral infection model

Mice were treated intranasally on day 0 of the experiments with either a 40,000 pfu dose of the H1N1 virus or 70,000pfu dose, equivalent to a lethal dose 75 (LD75), as indicated. The mice were monitored on a daily basis to see signs of infection. The weights of the mice were recorded and once a mouse weight loss exceeded 20%–25%, the mouse was euthanized. The endpoint of the experiments was set at day 12, to capture the peak of inflammation. For antibody treatment experiments, mice received anti-Notch4 mAb (10  $\mu$ g/ml) (clone HMN-4-14; Bio-X-Cell), anti-IL-6R $\alpha$  mAb (10  $\mu$ g/ml) (clone 15A7, Bio-X-Cell) or their respective isotype control antibodies, as indicated.

### Humanized mice H1N1 viral infection

NOD-*Prkdc*<sup>scid</sup>*Il2rg*<sup>tm1wjl</sup>/Sz (NSG) humanized mice were reconstituted with PBMCs from healthy control. Then, mice were treated with a sublethal dose of the virus as indicated intranasally on day 0. The mice were monitored on a daily basis to see signs of infection. The weights of the mice were recorded and once a mouse weight loss exceeded 20%–25%, the mouse was euthanized. For sublethal experiments, the endpoint of the experiment was set at day 12, to capture the peak of inflammation.

### Viral Load

Viral titers were determined by quantification of viral transcripts using reverse transcription (RT)-quantitative (q) PCR as previously described (Cho et al., 2012; Glenn et al., 2017; Moltedo et al., 2011). The collected lung tissue was weighed, and total RNA was isolated using RNeasy mini kit (QIAGEN). Purified RNA was converted into cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen) following the manufacturer's recommended procedures. Quantification of viral load was performed in 96-well plates and run on a QuantStudio 3 Real-Time PCR instrument (Applied Biosystems). The amplification was carried out using H1N1 nucleoprotein region specific primers: forward primer, 5'-GGGGGAAGCTCTCCACTAGA-3' and reverse primer, 5'-GTTGTGTGCTGATTTGGCC-3' in the presence of the Power SYBR Green Master Mix (Applied Biosystems). The PCR amplification cycle was set as 95°C for 5 min for initial denaturation, followed by 50 cycles of 95°C for 15 s, 60°C for 1 min. The standard curve was generated using 10-fold serial dilutions of constructed plasmid pcDNA3-NP (Addgene) by plotting each cycle threshold (CT) value against the log quantity of each standard plasmid copy number. Viral RNA copies were extrapolated from the standard curve using the sample CT value and represented as viral RNA copies per gram of tissue.

For determination of the viral load in the humanized mouse model, viral transcripts were quantitated using reverse transcription (RT)-quantitative (q) PCR as previously described (Cho et al., 2012; Glenn et al., 2017; Moltedo et al., 2011). Briefly, RNA was isolated from right upper lung lobe homogenates prepared in TRIzol (Sigma-Aldrich) and 1  $\mu$ g RNA as determined by a Nanodrop 2000 spectrophotometer (ThermoFisher) was converted to cDNA by reverse transcription using the protocol provided by the manufacturer (TaqMan Reverse Transcription Reagents, ThermoFisher). qPCR reactions in the presence of SYBR Green (FastStart Essential DNA Green Master Mix, Roche) were performed on a Light-Cycler 96 Instrument (Roche). Primers: Polymerase gene (PA), 5'-CGGTCAAATTCCTGCTGA-3' (forward) and 5'-CATTGGGTTCTCCATCCA-3' (reverse).

### Measurement of airway functional responses

Poly I:C-induced airway hyperreactivity (AHR) was measured, as previously described (Xia et al., 2018). Anesthetized mice were exposed to doubling concentrations of aerosolized acetyl- $\beta$ -methacholine (Sigma-Aldrich) by using a Buxco small-animal ventilator (Data Sciences International). The relative peak airway resistance for each methacholine dose, normalized to the saline baseline, was calculated.

### Lung histopathology staining

Paraffin-embedded lung sections were stained with hematoxylin and eosin (H&E) or Paraffin-acid-Schiff staining (PAS). The lung pathology was scored by blinded operators. Inflammation was scored separately for cellular infiltration around blood vessels and airways: 0, no infiltrates; 1, few inflammatory cells; 2, a ring of inflammatory cells 1 cell layer deep; 3, a ring of inflammatory cells 2–4 cells deep; 4, a ring of inflammatory cells of > 4 cells deep (Tachdjian et al., 2009). A composite score was determined by the adding the inflammatory scores for both vessels and airways.

### Dextran Leakage Assay

25  $\mu$ g of TRITC-Dextran (MW 40,000; Sigma) in 80  $\mu$ l saline was instilled intratracheally in each mouse. After one hour of dextran instillation, blood from the mice were collected retro-orbitally in sodium citrate solution, and the plasma was separated by centrifugation (2000 rpm, 15 minutes at 4°C). Leakage of dextran in the bloodstream is calculated as TRITC fluorescence in the plasma compared to plasma from mock-treated mice.

### Flow cytometric analysis of mouse and human cells

Antibodies against the following murine antigens were used for flow cytometric analyses: IL-4 (clone 11B11, catalog no: 504104 1:300 dilution, Biolegend), Foxp3 (FJK-16S, catalog no: 48-5773-82 1:300, Thermofisher), IFN $\gamma$  (XMG1.2, catalog no: 505825 1:300, Biolegend), IL-13 (eBio13a, catalog no.: 47-7133-82 1:300, Thermofisher), TNF (MP6-XT22, Catalogue no: 554419, 1:200, BD Biosciences), Helios (22F6, catalog no: 47-9883-42 1:200, Thermofisher), CD11c (N418, catalog no: 117318 1:500, Biolegend), CD11b (M1/70, catalog no: 101228 1:500, Biolegend), CD4 (GK1.5, catalog no: 100451, 1:500, Biolegend), CD206 (C068C2, Catalogue no: 141719, 1:300, Biolegend), CD163 (S15049I, Catalogue no: 155305 1:200, Biolegend), CD68 (FA-11, Catalogue no: 137023 1:200, Biolegend), CD80 (16-10A1, Catalogue no: 104711 1:200, Biolegend), F4/80 (BM8, Catalogue no: 48-4801-82 1:300, Thermofisher), MHCII (39-10-8, Catalogue no: 115006, 1:300, Biolegend), IL-33Ralpha (DIH9, Catalogue no: 145312 1:300, Biolegend), Lineage (anti-CD3/GR-1/CD11B/CD45-B220/TER 119) (Biolegend, 1:300 catalog no: 78022), CD3 (17A2, catalog no: 100203, 1:500, Biolegend), IL-17 (TC11-18H10.1, catalog no: 506922, 1:200, Biolegend), GR-1 (RB6-8C5, catalog no: 108406, 1:500, Biolegend), CD45 (30-F11, catalog no: 103140, 1:300, Biolegend), Notch4 (HMN4-14, catalog no: 128407 1:400, Biolegend), CD134 (DX-86, catalog no:17-1341-82, 1:400 Thermofisher), CTLA-4 (CD152) (UC10-4B9, catalog no: 106310, 1:400 Biolegend), CD223 (Ebio-C9B7W, catalog no:12-2231-83, 1:400 Thermofisher), CD279 (J43, catalog no:12-9985-82, 1:400 Thermofisher), IL-6R $\alpha$  (15A7, catalog no: BE0047, 1:200 Bio-X-Cell), Jagged1 (CD339) (HMJ1-29, catalog no:130908, 1:400 Biolegend), Amphiregulin polyclonal antibody (orb7378, 1:200, Biorbyt), IL-6R $\alpha$  (D7715A7, catalog 115813, 1:400 Biolegend), IL-18R $\alpha$  (BG/IL18RA, catalog 132903, 1:400 Biolegend), P-EGFR(D7A5, catalog no:D7A5, 1:200 Cell Signaling Technology), Anti-CD16/CD32 (93, catalog no: 101319, 1:1000 Biolegend). Antibodies against the following human antigens were used: CD3 (HIT3a, catalog no: 300318, 1:200, Biolegend), CD4 (RPA-T4, catalog no: 300530, 1:200, Biolegend), Foxp3 (PCH-101, catalog no: 48-4776-42, 56-4716-41, 1:100 Thermofisher), Helios (22F6, catalog no: 47-9883-42 1:100, Thermofisher), Notch1 (HMN1-519, catalog no: 566023, 1:300, BD PharMingen), Notch2 (HMN2-25, catalog no: 742291, 1:300, BD PharMingen), Notch3 (HMN3-21, catalog no: 744828, 1:300, BD PharMingen), Notch4 (HMN4-2, Catalogue no: 563269, 1:300, BD PharMingen), Yap1 (D8H1X, Catalogue no: 14729S, 1:100, Cell Signaling

Technology), beta-Catenin (196624, Catalogue no: IC13292V, 1:200, R&D system), CD25 (BC96, Catalogue no: 51-025-941 1:300, Thermofisher), IL-4 (MP4-25D2, Catalogue no: 500828 1:200, Biolegend), IL-13 (JES10-5A2, Catalogue no: 501912, 1:200, Biolegend), CCR4 (L291H4, Catalogue no: 359417 1:300, Biolegend), CXCR3 (G025H7, Catalogue no: 353708, 1:300 Biolegend), CRTH2 (BM16, Catalogue no: 350108 1:300, Biolegend), CD127 (A019D5, Catalogue no: 351320 1:300, Biolegend), IFN $\gamma$  (4S.B3, Catalogue no: 560741 1:200, BD Biosciences) and Amphiregulin polyclonal antibody (orb7378 1:200, Biorbyt), CD196 (G034E3, Catalogue no: 353423, 1:300 Biolegend). The specificity and optimal dilution of each antibody was validated by testing on appropriate negative and positive controls or otherwise provided on the manufacturer's website. Intracellular cytokine staining was performed as previously described (Charbonnier et al., 2015). Dead cells were routinely excluded from the analysis based on the staining of eFluor 780 Fixable Viability Dye (1:1000 dilution) (Thermofisher). Stained cells were analyzed on a BD LSR Fortessa cell analyzer (BD Biosciences) and data were processed using Flowjo (Tree Star Inc.).

### M1 and M2 gating strategy

M1 was defined as follows: CD45<sup>+</sup>CD4<sup>-</sup>F4/80<sup>+</sup>MHCII<sup>+</sup>CD68<sup>+</sup>CD80<sup>+</sup>CD86<sup>+</sup> while M2 macrophages were defined as follows: CD45<sup>+</sup>CD4<sup>-</sup>F4/80<sup>+</sup>MHCII<sup>+</sup>CD163<sup>+</sup>CD206<sup>+</sup>.

### Transcriptome Profiling

Treg cells were isolated from either *Foxp3*<sup>YFPcre</sup> or *Foxp3*<sup>YFPcre</sup> *Notch4* $\Delta/\Delta$  mice that were treated with Poly I:C as shown above. mRNA was isolated using QIAGEN RNeasy mini kit (QIAGEN). RNA was then converted into double-stranded DNA (dsDNA), using SMART-Seq v4 Ultra Low Input RNA kit (Clontech). dsDNA was then fragmented to 200-300 bp size, using M220 Focused-ultrasonicator (Covaris), and utilized for construction of libraries for Illumina sequencing using KAPA Hyper Prep Kit (Kapa Biosystems). Libraries were then quantified using Qubit dsDNA HS (High Sensitivity) Assay Kit on Agilent High Sensitivity DNA Bioanalyzer.

Gene-level read counts were quantified using feature Counts and the latest Ensembl mouse annotation (GRCm38.R101). Raw data were trimmed using Trimmomatic (version 0.39, default parameters), tool for Illumina NGS data. To identify differentially expressed genes, we used 3 algorithms: DESeq2 (version 1.26.0), edgeR (version 3.28.1) and Lima (3.42.2) Bioconductor packages with default parameters. Count tables were normalized to TPM (Transcripts per Million) for visualizations and QC. Sample clustering, path analyses and integration of the results were performed using a custom-made pipeline available upon request (Variant Explorer RNaseq). Transcripts were called as differentially expressed when the adjusted p values were below 0.05, fold-changes over  $\pm 1.5$  and false discovery rate (FDR) were below 0.05. For our path analyses, we tested 10,715 biological pathways from KEGG and GO annotations. We filtered the results using an adjusted p value below 0.01.

### QUANTIFICATION AND STATISTICAL ANALYSIS

Student's two-tailed t test, one- and two-way ANOVA and repeat measures two-way ANOVA with post-test analysis and log-rank test of groups were used to compare test groups, as indicated. Linear Regression was used for correlation analysis. For analysis of the human data, summary statistics were calculated using number (percentage) for binary and categorical data and mean (standard deviation) or median (interquartile range) for continuous data depending on the normality of the distribution. Logistic regression was performed to determine the association between Notch4 expression and mortality. Covariates including age, gender, and study site were selected based on *a priori* knowledge. In the case of highly correlated covariates, we chose the predictor that had the strongest univariate association between the potential predictor and outcome. In the final model, the outcome was death at any time after study enrollment, the predictors of interest were Notch4 expression and serum interleukin-6 levels, and covariates included age, gender, history of malignancy, and corticosteroid treatment. Analyses were performed in R version 3.6.1. Two-sided p values of < 0.05 were considered statistically significant.